New hope for kids with rare kidney disease
NCT ID NCT07498335
Summary
This study is testing an investigational drug called atrasentan in children and teenagers (ages 2 to 18) who have a kidney disease called IgA nephropathy. The main goal is to see if the drug safely reduces the amount of protein in the urine, which is a key sign of kidney damage. Participants will take the drug for up to two years while also continuing their standard kidney-protective medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.